^
Association details:
| Biomarker: | HSD3B1 1245A>C |
|---|---|
| Cancer: | Prostate Cancer |
| Drug Class: | CYP17A1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
Published date:
11/03/2020
Excerpt:
The result validated that the HSD3B1 (1245C) variant allele was associated with a shorter PFS (HR, 1.97; 95% CI, 1.39-2.79; P = 0.0001) (homozygous wild-type group) in men with prostate cancer when treated with ADT, however, a higher PFS (HR, 0.68; 95% CI, 0.48-0.96; P = 0.03) when treated with ADT and CYP17A1 inhibitor.
DOI:
10.1007/s00280-020-04192-z
